A Review of Interstitial Lung Diseases

Similar documents
A Review of Interstitial Lung Diseases. Paul J. Wolters, MD Associate Professor Department of Medicine University of California San Francisco

Case Presentations in ILD. Harold R. Collard, MD Department of Medicine University of California San Francisco

Update on Therapies for Idiopathic Pulmonary Fibrosis. Outline

IPF: Epidemiologia e stato dell arte

Financial disclosure COMMON DIAGNOSES IN HRCT. High Res Chest HRCT. HRCT Pre test. I have no financial relationships to disclose. Anatomy Nomenclature

11/10/2014. Multi-disciplinary Approach to Diffuse Lung Disease: The Imager s Perspective. Radiology

4/17/2010 C ini n ca c l a Ev E a v l a ua u t a ion o n of o ILD U dat a e t e i n I LDs

Non-neoplastic Lung Disease II

INTERSTITIAL LUNG DISEASE. Radhika Reddy MD Pulmonary/Critical Care Long Beach VA Medical Center January 5, 2018

IPF - Inquadramento clinico

Differential diagnosis

5/9/2015. Multi-disciplinary Approach to Diffuse Lung Disease: The Imager s Perspective. No, I am not a pulmonologist! Radiology

Outline Definition of Terms: Lexicon. Traction Bronchiectasis

Manish Powari Regional Training Day 10/12/2014

Overview of Idiopathic Pulmonary Fibrosis: Diagnosis and Therapy

Pathologic Assessment of Interstitial Lung Disease

Multidisciplinary Diagnosis in Action: Challenging Case Presentations

Diagnosing Idiopathic Pulmonary Fibrosis on Evidence-Based Guidelines

Disclosures. Traditional Paradigm. Overview 4/17/2010. I have relationships with the following organizations and companies:

CTD-related Lung Disease

Liebow and Carrington's original classification of IIP

Case 1 : Question. 1.1 What is the intralobular distribution? 1. Centrilobular 2. Perilymphatic 3. Random

Challenges in the Diagnosis of Interstitial Lung Disease

Unpaid scientific collaborator & advisor with Veracyte, Inc.

Challenges in the Diagnosis of Interstitial Lung Disease

Progress in Idiopathic Pulmonary Fibrosis

Disclosures. Fibrotic lung diseases: Basic Principles, Common Problems, and Reporting. Relevant financial relationships: None. Off-label usage: None

Diagnostic challenges in IPF

DIFFERENCES IN FIBROPROLIFERATIVE HEALING IN EXOGENEOUS AND IDIOPATHIC ILDs. ARE THERE ANY?

Daria Manos RSNA 2016 RC tment-sites/radiology/contact/faculty/dariamanos.html

Case 1: Question. 1.1 What is the main pattern of this HRCT? 1. Intralobular line 2. Groundglass opacity 3. Perilymphatic nodule

NONE OVERVIEW FINANCIAL DISCLOSURES UPDATE ON IDIOPATHIC PULMONARY FIBROSIS/IPF (UIP) FOR PATHOLOGISTS. IPF = Idiopathic UIP Radiologic UIP Path UIP

Timely Topics in Pulmonary Medicine

Radiologic Approach to Smoking Related Interstitial Lung Disease

International consensus statement on idiopathic pulmonary fibrosis

Guidelines for Diagnosis and Treatment of IPF

Acute and Chronic Lung Disease

Diffuse Interstitial Lung Diseases: Is There Really Anything New?

Katerina M. Antoniou, MD, PhD As. Professor in Thoracic Medicine ERS ILD Group Secretary Medical School, University of Crete Prague, June 2014

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Lines and crackles. Making sense of ILD

Diagnosing ILD. What is important in 2016? Chris Grainge

Annual Rheumatology & Therapeutics Review for Organizations & Societies

HYPERSENSITIVITY PNEUMONITIS

Usual Interstitial pneumonia and Nonspecific Interstitial Pneumonia. Nitra and the Gangs.

DIAGNOSTIC NOTE TEMPLATE

Idiopathic Pulmonary Fibrosis Treatable and Not Idiopathic

Epidemiology and classification of smoking related interstitial lung diseases

UIP Possibile e Probabile

COI: no conflicts of interest to declare

Connective Tissue Disorder- Associated Interstitial Lung Disease (CTD-ILD) and Updates

Disclosures. Clinical Approach: Evaluating CTD-ILD for the pulmonologist. ILD in CTD. connective tissue disease or collagen vascular disease

Interstitial Lung Disease (ILD)

Hypersensitivity Pneumonitis Common Diagnostic and Treatment Dilemmas

INTERSTITIAL LUNG DISEASES: FOCUS ON IDIOPATHIC PULMONARY FIBROSIS (IPF)

Bronchoalveolar Lavage and Histopathologic Diagnosis Based on Biopsy

The Egyptian Journal of Hospital Medicine (July 2017) Vol.68 (2), Page

HRCT in Diffuse Interstitial Lung Disease Steps in High Resolution CT Diagnosis. Where are the lymphatics? Anatomic distribution

Idiopathic Pulmonary of Care

How to identify interstitial pneumonias.

Déjà vu all over again

T he diagnostic evaluation of a patient with

Idiopathic interstitial pneumonias (IIPs) are a group of

A case of a patient with IPF treated with nintedanib. Prof. Kreuter and Prof. Heussel

The ABC s of ILD LIP AIP NSIP

Thoracic lung involvement in rheumatoid arthritis: Findings on HRCT

Pulmonary Test Brenda Shinar

Chest imaging II. Interstitial lung diseases

June 2013 Pulmonary Case of the Month: Diagnosis Makes a Difference. Lewis J. Wesselius, MD 1 Henry D. Tazelaar, MD 2

Case 1. Case Presentation. Disclosure Statement. ILD: What the generalist needs to know

Histopathologic Approach to Interstitial Lung Disease

INTERSTITIAL LUNG DISEASE Dr. Zulqarnain Ashraf

Pulmonary manifestations of CTDs Diagnosis, differential diagnosis and treatment

Bronkhorst colloquium Interstitiële longziekten. Katrien Grünberg, klinisch patholoog

I have no relevant conflicts of interest to disclose

Criteria for confident HRCT diagnosis of usual interstitial pneumonia (UIP)

Combined Unclassifiable Interstitial Pneumonia and Emphysema: A Report of Two Cases

TBLB is not recommended as the initial biopsy option in cases of suspected IPF and is unreliable in the diagnosis of rare lung disease (other than

I don t need you. Disclosure Statement. Pathology Approach to ILD 11/5/2016. Kirk D. Jones, MD UCSF Dept of Pathology

Patient with IPF and no honeycombing on HRCT. Case 1 Demosthenes Bouros, Vasilios Tzilas University of Athens

An earlier and more confident diagnosis of idiopathic pulmonary fibrosis

Hypersensitivity Pneumonitis: Spectrum of High-Resolution CT and Pathologic Findings

CLEARING THE AIR ON DIFFUSE PARENCHYMAL (INTERSTITIAL) LUNG DISEASE (ILD)

UIP OR NOT UIP PATTERN: THAT IS NOT THE ONLY QUESTION!

The radiological differential diagnosis of the UIP pattern

Systemic lupus erythematosus (SLE): Pleuropulmonary Manifestations

Key words: CT scanners; interstitial lung diseases; polymyositis-dermatomyositis; x-ray

Idiopathic Pulmonary Fibrosis: The Importance of Qualitative and Quantitative Phenotyping

PFF HEALTH CARE PROFESSIONAL WEBINAR SERIES. Welcome!

Hypersensitivity Pneumonitis: Epidemiology and Classification

Interstitial Lung Disease in the Connective Tissue Diseases

Imaging findings in Hypersensitivity Pneumonitis - a pictorical review.

Cryptogenic Organizing Pneumonia Diagnosis Approach Based on a Clinical-Radiologic-Pathologic Consensus

Careful histopathological evaluation has shown the traditionally clinical diagnosis of

Initial presentation of idiopathic pulmonary fibrosis as an acute exacerbation

SCLERODERMA LUNG DISEASE: WHAT THE PATIENT SHOULD KNOW

Replacement of air with fluid, inflammatory. cells or cellular debris. Parenchymal, Interstitial (Restrictive) and Vascular Diseases.

Spectrum of Findings on HRCT in Evaluation of Interstitial Lung Diseases: A Single Centre Prospective Observational Study

Interstitial Lung Disease ILD: Definition

Transcription:

Outline A Review of Interstitial Lung Diseases Paul J. Wolters, MD Associate Professor Department of Medicine University of California San Francisco Overview of diagnosis in ILD Why it is important Definition/Classification High-resolution CT scan Multidisciplinary approach Cases Interactive format (ARS) Review of radiology and pathology Questions/Discussion Why it is Important to be Aware of ILD s Don t stop with pulmonary fibrosis Reasons for a specific diagnosis: Many forms are treatable Treatments depend on diagnosis Prognosis varies Eligibility for clinical trials 1

Clinical Classification Clinical History Pulmonary Fibrosis Exposure-related: - Occupational - Environmental - Avocational - Medication Desquamative interstitial pneumonia (DIP) Acute interstitial pneumonia (AIP) Nonspecific interstitial pneumonia (NSIP) Idiopathic interstitial pneumonia (IIP) Idiopathic pulmonary fibrosis (IPF) Connective tissue disease: - Scleroderma - Rheum. arthritis - Sjogrens - UCTD Respiratory bronchiolitis interstitial lung dis. (RBILD) Cryptogenic organizing pneumonia (COP) Lymphocytic interstitial pneumonia (LIP) Other: - Sarcoidosis - Vasculitis/Diffuse alveolar hemorrhage (DAH) - Langherhans cell histiocytosis (LCH) - Lymphagioleiomyomatosis (LAM) - Pulmonary alveolar proteinosis (PAP) - Eosinophilic pneumonias - Neurofibromatosis - Inherited disorders - Chronic aspiration - Inflammatory bowel disease Idiopathic usual interstitial pneumonitis (UIP) = IPF nonspecific interstitial pneumonitis (NSIP) desquamative interstitial pneumonitis (DIP) respiratory bronchiolitis ILD (RBILD) acute interstitial pneumonitis (AIP) Unclassified Drugs Occupational/Environmental -Asbestos -Birds/Molds/Organic Material (HP) Collagen Vascular Joint c/o Sicca sx Skin rash Raynaud s Exam: Clues to diagnosis CXR is Not Useful for Differentiating ILD s Lung: Crackles on exam. Findings c/w sarcoid: Uveitis, skin rash, erythema nodosum, hepatomegaly. Findings c/w CVD: Synovitis, rash, sclerodactaly. Findings c/w IPF: Clubbing HP CVD-ILD IPF NSIP 2

High-resolution CT () is the Key to Diagnosing ILD s 1-1.5 mm collimation Images taken every 10 mm Supine, prone and expiratory images Pattern of abnormality on scan may suggest a specific ILD. findings guide subsequent diagnostic tests. findings may be sufficient for diagnosis. Usual Interstitial Pneumonia (UIP) Nonspecific Interstitial Pneumonitis (NSIP) Irregular lines in a patchy, basilar, subpleural distribution Traction bronchiectasis minimal Ground glass opacities. Honeycomb lung Ground glass opacities (10) Consolidation (98%) Nodules (96%) Traction bronchiectasis (95%) Intralobular reticulation (87%) Lower lobe predominance 3

Desquamative Interstitial Pneumonia (DIP) Hypersensitivity Pneumonitis Ground glass opacity with a basilar, subpleural, and lower lobe distribution Lower lobe reticular opacities Subacute phase : multifocal or diffuse GGO poorly defined centrilobular nodules Subacute and chronic phases : mosaic perfusion air trapping on expiratory images CT may be normal in some cases Sarcoidosis Diagnostic Algorithm Perilymphatic nodules Peribronchial nodules GGO Upper lobe predominant, +/- fibrosis Detailed history, PE + Suspected PF + PFTs/Labs Diagnostic Non-diagnostic 1. IPF 2. Sarcoidosis 3. CV-ILD 4. Hypersensitivity pneumonitis 5. Rare disease (LAM, PAP) Lung biopsy 4

Multidisciplinary approach Agreement increased with multidisciplinary approach Agreement (κ) 1.0 0.9 0.8 0.7 0.6 0.5 0.4 0.3 0.2 0.1 0 1 2 3 4 5 Step Assessment Method Information Provided 1 Individual 2 Individual 3 4 Discussion (clinician and radiologist) Individual (clinician, radiologist and pathologist) 5 Discussion, clinical data, clinical data, clinical data, SLB, clinical data, SLB Case 1 Step Modified from: Flaherty KR, et al. Am J Respir Crit Care Med. 2004;170:904-910. 57 year old man Case 1 Abnormal CXR 3 months prior to presentation (notes normal CXR from 5 years ago) Mild dyspnea on exertion, no cough PMH: GERD for 30 years Meds: omeprazole 40mg daily Case 1 Social: lifetime non-smoker, some mold in home, pharmacist Family: no history of ILD 114/73 hr 70 rr 16 96% RA (93% walking) Dry inspiratory crackles at both bases Normal cardiac examination No clubbing, joint deformities, rashes 5

PFTs FVC 5.10 (83%) FEV1 4.42 (9) FEV1/FVC 0.87 TLC 7.40 (88%) DLCO 23.41 (57%) Case 1 CXR What additional testing would you perform next in this patient? 1. Bronchoalveolar lavage (BAL) 2. BAL and transbronchial biopsy 3. Serological evaluation 4. High resolution CT scan 5. Surgical lung biopsy 6. No additional testing; diagnosis is clear 98% 2% 1 2 3 4 5 6 6

7

Serological evaluation What additional testing would you perform next in this patient? ANA negative 1. Bronchoalveolar lavage (BAL) RF = 4 2. BAL and transbronchial biopsy 3. Surgical lung biopsy 4. No additional testing; diagnosis is clear 4 33% 27% 1 2 3 4 8

VATS VATS Usual Interstitial Pneumonia (UIP) Temporal heterogeneity Subpleural accentuation of fibrosis Regions of normal lung Microscopic honeycombing Fibroblast Foci Diagnosis of IPF Management Enrolled in clinical trial Pulmonary rehabilitation Weight loss (if overweight) Lung transplant referral 9

IPF: Published Definition Survival Median survival for IPF is 2 3 years No proven therapy A specific form of chronic fibrosing interstitial pneumonia limited to the lung and associated with the histologic appearance of usual interstitial pneumonia on surgical lung biopsy. IPF ATS/ERS. Am J Respir Crit Care Med. 2000;161:646-664. Modified from Bjoraker JA. Am J Respir Crit Care Med. 1998;157:199-203. Case 2 Case 2 63-year-old woman 5-month history of shortness of breath and nonproductive cough PMH: hypertension, treated for TB exposure in 1980, arthritis Medications: diltiazem 10

Case 2 Social: former smoker (18 pk/yrs); office worker. Family: No history of ILD 135/80 hr 90 rr 14 94% RA (9 walking) Dry inspiratory crackles at both bases Normal cardiac examination No clubbing, joint deformities, rashes CXR What additional testing would you perform next in this patient? 1. Bronchoalveolar lavage (BAL) 2. BAL and transbronchial biopsy 3. Serological evaluation 4. High resolution CT scan 5. Surgical lung biopsy 6. No additional testing; diagnosis is clear 92% 2% 4% 2% 1 2 3 4 5 6 11

12

Serological evaluation ANA 1:80, speckled RF = 18, cyclic citrullinated antibody (CCP) negative What additional testing would you perform next in this patient? VATS 1. Bronchoalveolar lavage (BAL) 2. BAL and transbronchial biopsy 3. Surgical lung biopsy 4. No additional testing; diagnosis is clear 69% 22% 9% 1 2 3 4 13

VATS VATS Nonspecific Interstitial Pneumonitis (NSIP) Uniform involvement of the lung with Septal thickening Interstitial inflammation (lymphocytes) +/- Fibrosis What additional testing would you perform next in this patient? 1. Bronchoalveolar lavage (BAL) 2. BAL and transbronchial biopsy 3. Additional serologies 4. No additional testing; diagnosis is clear 39% 61% 1 2 3 4 14

RNP negative Scl70 negative Additional serologies SSA, SSB negative Jo-1 negative, CPK 104 Diagnosis of NSIP Management Treated with prednisone and mycophenolate (CellCept) Pulmonary rehabilitation NSIP IPF NSIP Distinguishing NSIP from UIP is a challenge! Patients usually younger, more likely to be women Honeycombing on is uncommon in NSIP Surgical biopsy shows diffuse thickening of alveolar septae and few if any fibroblast foci 15

IPF NSIP IPF NSIP NSIP The diagnosis of NSIP should prompt you to go back to look for an etiology Occult connective tissue disease Drug reaction Hypersensitivity pneumonitis Case 3 16

43 year old man Case 3 Subacute progressive dyspnea Case 3 Social: non-smoker, banker, no known exposures, no pets. Family: no history of ILD PMH: mild obstructive sleep apnea on CPAP 6 cm H20, seasonal allergies Meds: cetirizine, multivitamin BP 116/56, hr 60, rr16, 98% RA (88% walking) Moderately obese Lungs clear to auscultation Case 3 CXR PFTs: FVC 3.17 (73%) FEV1 2.43 (77%) FEV1/FVC 0.77 TLC 4.65 (82%) DLCO 15.1 (58%) 17

What additional testing would you perform next in this patient? 1. Bronchoalveolar lavage (BAL) 2. BAL and transbronchial biopsy 3. Echocardiogram 4. High resolution CT scan 5. Surgical lung biopsy 6. No additional testing; diagnosis is clear 98% 3% 1 2 3 4 5 6 18

expiratory views 19

expiratory views expiratory views Serological Evaluation What additional testing would you perform next in this patient? ANA negative RF 12 SS-A, SS-B negative 1. Bronchoalveolar lavage (BAL) 2. BAL and transbronchial biopsy 3. Surgical lung biopsy 4. No additional testing; diagnosis is clear 68% 18% 15% 1 2 3 4 20

VATS Biopsy: Low Power VATS Biopsy: High Power VATS Biopsy: High Power Hypersensitivity Pneumonitis Airwaycentric inflammation Poorly formed granuloma (giant cell) Areas of organizing pneumonia 21

What additional testing would you perform next in this patient? Additional history 1. Bronchoalveolar lavage (BAL) 2. Sputum culture 3. Serum precipitins 4. Additional history 5. No additional testing; diagnosis is clear 8% 26% 5 16% Patient recently moved to a new home built on the site of a former pigeon farm. There is ongoing construction of new units around his home and lots of dust. 1 2 3 4 5 Hypersensitivity Pneumonitis Thank you! Management Remove antigen (Relocated from new home) Treat with prednisone Pulmonary rehabilitation 22

UCSF Interstitial Lung Disease Clinic Clinical Coordinator: (415) 353-8764 Clinic fax: (415) 353-2568 http://www.ucsfhealth.org/adult/medical_services/pulmonary/ild/index.html 23